The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone

[1]  Weiping Yang,et al.  Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer , 2009, Anti-cancer drugs.

[2]  E. Vasile,et al.  Long-Term Outcome of Initially Unresectable Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Followed by Radical Surgery of Metastases , 2009, Annals of surgery.

[3]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[4]  P. Fayers,et al.  Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach. , 2007, European journal of cancer.

[5]  J. Ajani,et al.  Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  W. Kang,et al.  Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  H. Horio,et al.  Resection of Solitary Pulmonary Metastasis from Gastric Cancer , 2007 .

[8]  A. Pavlick,et al.  Phase 2 trial of talabostat and cisplatin in patients with stage IV melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Norman,et al.  Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Ajani.  Evolving chemotherapy for advanced gastric cancer. , 2005, The oncologist.

[11]  A. Bottomley,et al.  Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. , 2004, European journal of cancer.

[12]  T. Oda,et al.  Long-Term Survival Achieved by Repeated Resections of Metachronous Pulmonary and Adrenal Metastases of α-Fetoprotein-Producing Gastric Cancer: Report of a Case , 2004, Surgery Today.

[13]  J. Cashy,et al.  FACT-Gastric: A new international measure of QOL in gastric cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  T. Oda,et al.  Long-term survival achieved by repeated resections of metachronous pulmonary and adrenal metastases of alpha-fetoprotein-producing gastric cancer: report of a case. , 2004, Surgery today.

[15]  M. Makuuchi,et al.  Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients. , 2003, Surgery.

[16]  Yuman Fong,et al.  Improvement in Perioperative Outcome After Hepatic Resection: Analysis of 1,803 Consecutive Cases Over the Past Decade , 2002, Annals of surgery.

[17]  R. Jakesz,et al.  Analysis of hepatic resection of metastasis originating from gastric adenocarcinoma , 2002, Journal of Gastrointestinal Surgery.

[18]  T. Kido,et al.  A LONG-TERM SURVIVOR AFTER EARLY GASTRIC CANCER WITH TWO TIMES OF LUNG METASTASES WHICH WERE SUCCESSFULLY RESECTED , 2002 .

[19]  H. Maeta,et al.  Hepatic Resection for Metastatic Tumors From Gastric Cancer , 2002, Annals of surgery.

[20]  S. Miyoshi,et al.  Four Cases of Resected Pulmonary Tumor Metastatic From Gastric Cancer. , 2002 .

[21]  K. Hirose,et al.  Efficacy of Continuous Hyperthermic Peritoneal Perfusion for the Prophylaxis and Treatment of Peritoneal Metastasis of Advanced Gastric Cancer: Evaluation by Multivariate Regression Analysis , 1999, Oncology.

[22]  R. Tsuchiya,et al.  Surgical resection of pulmonary metastases from gastric cancer , 1998, Journal of surgical oncology.

[23]  G. Tsumatori,et al.  Five cases of surgically resected pulmonary metastases from gastric cancer : relation between the expression of carbohydrate antigens and metastasis , 1998 .

[24]  I. Judson,et al.  First demonstration of anti-lymphoma activity of BCL-2 antisense molecule-G3139; Results of phase I/IIA clinical trial , 1997 .

[25]  T. Hickish,et al.  Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Takuma Sasaki,et al.  Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. , 1996, Surgery.

[27]  S. Pyrhönen,et al.  Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. , 1995, British Journal of Cancer.

[28]  A. Petroianu,et al.  Modified therapy with 5‐fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer , 1993, Cancer.

[29]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.